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Abstract
Oncologists are aware of the vulvovaginal atrophy (VVA) problem in breast cancer survivors (BCSs) but only
half of them illustrate VVA as a possible consequence of treatment. Forty-one percent of the oncologists refer
BCSs to gynaecologist to define VVA treatment, whereas 35.1% manages it alone. Nonhormonal treatments
are preferred by most oncologists (71%). The main reason not to prescribe vaginal estrogen therapy in BCSs is
the fear of increased cancer recurrence, the possible interference with tamoxifen, or aromatase inhibitors and
the fear of medical litigation.
Background: Vulvovaginal atrophy (VVA) is a relevant problem for breast cancer survivors (BCSs), in particular for
those who receive aromatase inhibitors (AIs). We conducted a survey, to assess the attitude of oncologists toward the
diagnosis and treatment of VVA in BCSs. Materials and Methods: In 2015, 120 computer-assisted Web interviews
were performed among breast oncologists. Results: According to oncologists’ perceptions, 60% of postmenopausal
BCSs and 39.4% of premenopausal BCSs will suffer from VVA. Despite that none of the physicians considered VVA as
a transient event or a secondary problem in BCSs, only half of the oncologists (48%) directly illustrated VVA to the
patients as a possible consequence. Forty-one percent of the oncologists refer BCSs to gynaecologist to define VVA
treatment, whereas 35.1% manages it alone. Nonhormonal treatments are preferred by most oncologists (71%). The
main reason not to prescribe vaginal estrogen therapy in BCSs is the fear of increased cancer recurrence, the possible
interference with tamoxifen, or AIs and the fear of medical litigation. Conclusion: VVA is a relevant problem for BCSs.
Great effort should be done to correctly inform health care providers about VVA problems and on the different possible
available treatments.
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Every year, an increasing number of new cases of breast cancer are
diagnosed among women in reproductive age. Many breast cancer
survivors (BCSs), especially young women, undergo menopausal
symptoms, as direct consequences of cancer treatment chemo-
therapy, tamoxifen, aromatase inhibitors (AIs), and ovarian
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http://dx.doi.org/10.1016/j.clbc.2017.05.008therapy, particularly those using AIs,1,2 refer to vulvovaginal atrophy
(VVA) as one of the most unpleasant side effects.3
Published surveys on BCSs reveal that VVA has been reported by
42% to 70% of postmenopausal patients and those women rarely
discuss the problem with health care providers.4
Furthermore, the problem of VVA, in BCSs, will increase
because of the practice of prolonged therapy with tamoxifen or AIs;
to properly manage this side effect oncologists as well as patients
should be aware about the disease and therapeutic options.5,6
Symptoms of VVA include dryness, burning, itching, dyspar-
eunia, and bleeding after sexual activity, with a high effect on
quality of life (QoL), including relationship, sexual satisfaction, and
self-esteem.7
Recently, the term, genitourinary syndrome of menopause (GSM),
has been proposed instead of VVA, to include any genital, urinary,
and sexual signs and symptoms associated with menopause.8Clinical Breast Cancer Month 2017 - 1
Figure 1 Treatments Prescribed to Treat Vulvovaginal Atrophy.
Nonhormonal, Local, or Systemic Hormonal Drugs,
and Other (Mainly Alternative Medicine Products)
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Vaginal Atrophy in Breast Cancer SurvivorsGenitourinary syndrome of menopause is usually reversible with
hormone replacement therapy (HRT). Local estrogen treatment is
the most used approach for symptom management and illness
healing.9,10 However, in BCSs, estrogen administration has safety
concerns, because of the hypothetical risk of cancer recurrence.11
Therefore, in this setting of patients, the American College of
Obstetricians and Gynecologists (ACOG) recommends a local
nonhormonal approach as first-line treatment for GSM leaving
estrogens to patients unresponsive to nonhormonal therapies.12
It is not clear which health care provider (gynecologist,
oncologist, or family doctor) might deal with the VVA. Moreover,
no agreement is reached among the different specialists.
We performed this survey among oncologists in breast cancer to
investigate their attitude toward the VVA problem in BCSs.
Materials and Methods
One hundred twenty computer-assisted Web interviews
(CAWIs) were performed from May 18, 2015 to June 8, 2015 to
Italian breast oncologists, throughout the country (39.2% [47/120]
north, 20% [24/120] center, 40.8% [49/120] south).
The interview was planned in 3 different sections to determine
the number of breast patients followed per year, the adjuvant
treatment prescribed according to menopausal status, the attitude
toward the assessment and diagnosis of VVA symptoms, and the
knowledge concerning VVA treatment options.
To describe the attitude of oncologists toward VVA, they were
asked about: (1) the perception of VVA grade among patients
treated with hormonal depletion therapy; (2) clinical relevance
granted to VVA; (3) first time discussing VVA with patients; and
(4) primary measure as soon as the patient reveals VVA.
Furthermore, to evaluate oncologist experience in VVA treatment
options, the following data were collected: (1) what kind of drugs
they used in the treatment of VVA; and (2) their attitude toward
hormonal or nonhormonal drugs. The attitude of the patient when
hormonal drugs were prescribed was also reported.
Results
One hundred twenty oncologists (52.5% [63/120] male and
47.5% [57/120] female), belonging to several centers were inter-
viewed using the CAWI. A dedicated breast care unit was present in
64.2% of the hospitals, with a median of 240 new breast cancer
diagnoses per year. Moreover, in 12% of the centers the median of
new breast cancer diagnoses was more than 410 per year. The
median number of breast cancer-naive patients starting adjuvant
hormonal therapy was 63 per year; in 13.3% of centers, this median
value reached more than 100 cases per year.
Breast oncologists’ attitude toward adjuvant treatment prescrip-
tion is in accordance with the most recent guidelines on breast
cancer treatment, preferring AIs to tamoxifen.13 According to our
survey, in Italy, the first choice (65% [29/44] of cases), is tamoxifen
with ovarian suppression as antihormone adjuvant treatment in
premenopausal women; AIs with ovarian suppression are prescribed
only in 15% (7/44) of cases. In postmenopausal women, the on-
cologists prescribe AIs as first choice treatment (83% [63/76] of
cases) whereas tamoxifen is prescribed only in 17% (13/76) of pa-
tients. In one-fourth of the patients, in both groups, extended
therapy is prescribed (26% [11/44] and 22% [17/76], respectively).nical Breast Cancer Month 2017For pre- as well as postmenopausal patients, the compliance to
the standard 5-year adjuvant antihormone treatment is approxi-
mately 80% (83% [36/44] and 79% [60/76], respectively) as
referred by the oncologist.
According to oncologist opinion, in patients using adjuvant
hormonal treatment, 60% (46/76) of postmenopausal and 39%
(17/44) of premenopausal women experienced VVA. In post-
menopausal patients, VVA grade has been considered mild, mod-
erate, or severe in 43% (33/76), 40% (30/76), and 17% (13/76) of
cases, respectively. Every participant is conscious that VVA strongly
affects sexual health and increases probability of urinary tract
infections.
Despite that none of the physicians considered VVA as a tran-
sient event or a secondary problem in BCSs, only half of them (48%
[58/120]) explain to the patients that VVA could be a consequence
of iatrogenic menopause or AIs treatment. In most of the cases,
VVA is debated during the follow-up visit, in the cases for which the
patient complains about symptoms with the oncologists (56.9%
[68/120]) or with the nurse (14% [17/120]). The oncologist
address the problem of VVA only in 26.5% (31/120) of cases, with
no differences in relation to doctor’s sex. Oncologists are aware of
paying inadequate attention to the problem (85% [102/120] of the
answers) and they complain to not receive enough information on
this topic (85% [102/120] of the answers).
Forty-one percent (49/120) of the oncologists indicated they
refer the patient to the gynecologist whereas another 35.1%
(42/120) directly describe treatment options to the patient.
Eleven percent (13/120) of patients do not require or refuse any
kind of treatment; in contrast, 12% (14/120) of women manage the
VVA with self-prescription.
As expected, nonhormonal treatments (lubricants or moisturizers,
in the same proportion) are prescribed in most of the cases (71.1%
[85/120]). Vaginal estrogen therapy is prescribed by 21% (25/120)
of the oncologists and HRT is considered only by a minority (4%
[5/120]; Figure 1).
Nonhormonal treatments are considered safe by 90% (108/120)
of the oncologists and effective only by 30% (36/120) of them;
Figure 2 Oncologist’s Perspective of Safety and Efficacy for (A) Nonhormonal and (B) Hormonal Therapy to Treat Vulvovaginal Atrophy
in Breast Cancer Patients, According to a Visual Analogue Scale (Numbers Indicate 1 for Minimum and 10 for Maximum)
Nicoletta Biglia et alconversely, hormonal treatment with vaginal estrogens is considered
safe only by 15% (18/120) and effective by 79.2% (95/120) of
oncologists (Figure 2).
Prescription of local hormonal therapy is driven by different
reasons, mainly in the presence of severe dyspareunia symptoms,
interfering with sexual life (51.7% [62/120]), also upon patient
request (26.7% [32/120]), and for recurrent vaginal or urinary in-
fections (16.7% [20/120]).
Of the oncologists, only 24.2% (29/120) prescribe vaginal es-
trogen therapy for patients with nonhormone-dependent breast
cancer; only 7.5% (9/120) prescribe this therapy to patients with
hormone-dependent breast cancer, at the end of antihormone
adjuvant treatment. In 15% (18/120) of the cases, the oncologist
does not prescribe hormonal drugs to treat breast cancer patients.
Moreover, if a gynecologist prescribes vaginal estrogen therapy,
only 21.5% (26/120) of the oncologists confirm the prescription,
and 20.8% (25/120) confirm the prescription only for a short
period or just if the patient has nonhormone-dependent breastcancer (18.9% [23/120]), and 20.4% (25/120) of them do not
agree at all.
The main reason to not prescribe vaginal estrogen therapy in
BCSs is the probability of increased cancer recurrence, mentioned
by 70.8% (85/120) of the oncologists, followed by interference with
tamoxifen or AIs. Last, doctors might encounter a lawsuit by the
patient if a relapse due to estrogen therapy occurs.
When the oncologist prescribes hormonal therapy, a significant
percentage of women refuse to take it (43% [52/120]), whereas
36.5% (43/120) ask for reassurance before using it. However,
20.5% (25/120) of women accept vaginal estrogen prescription
especially in the presence of severe symptoms.
Regarding oncologists’ knowledge about different available
vaginal estrogen preparations, standard high-dose formulation was
mentioned by 70% (84/120) of them, whereas 52.5% [63/120]
prescribe low-dose and gel formulations. Furthermore, only 1.7%
(2/120) of the oncologists knew of new treatment options, such as
vaginal laser.Clinical Breast Cancer Month 2017 - 3
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Vulvovaginal atrophy is one of the most frequently reported side
effects by BCSs, recurrent among young women forced to prema-
ture menopause and for those using AIs,2,14 affecting sexual health
and with negative effect on QoL.1,3,15 Younger women have higher
rates of sexual dysfunction, even beyond the treatment period.16,17
A QoL analysis including 1722 premenopausal patients, with hor-
mone receptor-positive breast cancer randomly assigned to receive
adjuvant treatment (tamoxifen with ovarian function suppression or
tamoxifen alone for 5 years), showed loss of sexual interest at 6
months and vaginal dryness for up to 60 months, in patients who
received tamoxifen with ovarian function suppression with respect
to that in patients who received tamoxifen alone.18
In the literature, it is reported that up to 20% of BCSs consider
stopping antihormone therapy because of menopausal symp-
toms.19,20 In accordance with literature, in our survey to investigate
the attitude of breast oncologists toward the VVA problem in BCSs,
20% of pre- and postmenopausal patients stop antihormone treat-
ment, probably because of side effects such as VVA.
Oncologists are aware that VVA is a frequent problem among
BCSs, with 60% of postmenopausal women and 40% of younger
BCSs with the complaint of VVA. Furthermore, oncologists know
that VVA is an important issue for BCSs, being of moderate or
severe grade in most of the cases.
The oncologists are conscious that VVA strongly affects women’s
sexual health and that it can increase probability of urinary tract
infections.
The term GSM has been recently proposed instead of VVA,
because it better describes genital, urinary, and sexual areas involved.8
In contrast to vasomotor symptoms that usually improve over
time even without treatment, GSM is a chronic condition, unlikely
to resolve spontaneously, and often progressive if left untreated21: in
our survey, no one considered VVA as a temporary problem.
Only half of the oncologists directly describe VVA to women as a
possible consequence of adjuvant treatments, even if they do not
consider VVA a minor problem. In most of the cases, the VVA is
discussed during the follow-up visit, only if the patient complain
about symptoms.
It is well described in the literature that, despite the prevalence
and associated burden of GSM, the condition is often inadequately
addressed in medical practice.21
For the choice of the more appropriate treatment for VVA in
BCSs, most of the oncologists refer patients to the gynecologist,
whereas 35% of them discuss treatment options with the patients,
directly.
In our survey, approximately 10% of women did not require
or refused treatment and another 10% managed the problem with
self-prescription.
According to the available current guidelines, nonhormonal
vaginal moisturizers and lubricants are recommended as first-line
treatment for BCSs.9,11 In our survey, oncologists prescribed, in
most of the cases, nonhormonal treatments (lubricants or mois-
turizers in the same proportion), which are considered safe, even if
not completely effective.
In our survey, HRT is considered only by 4% of the oncologists
and only for women with important vasomotor symptomsnical Breast Cancer Month 2017associated with VVA. Available guidelines consider HRT contra-
indicated in BCSs9,11 after the results of the HABITS22,23 and
Stockholm trials.24 In addition, a trial on tibolone, a compound
alternative to conventional HRT, which shows estrogenic, proges-
togen, and androgenic properties, was prematurely stopped because
of a significant increase of recurrences in the group of BCSs treated
with tibolone compared with the placebo group.25
Vaginal estrogen administration is the preferred way of delivery
when vaginal symptoms are the only condition in postmenopausal
women. It is more effective than systemic estrogen administration in
the relief of symptomatic VVA, with 80% to 90% of women who
report a favorable response.10 Furthermore, vaginal estrogens also
improve sensory urgency and reduce the frequency of urinary tract
infections.9
Only a few trials have been conducted to investigate vaginal
estrogen therapy in BCSs suffering from VVA.26-32 The North
American Menopausal Society states that there are few reports
regarding the safety of local estrogens in BCSs: patients who do not
respond to nonhormonal therapies might discuss the risks and
benefits of low-dose vaginal estrogens with the oncologist.11
Systemic absorption can occur with conventional doses of vaginal
estrogen therapy, particularly in the case of atrophic vagina.33 Low-
dose local estrogen therapy is considered to have a lower risk profile
compared with standard doses because it produces very low serum
levels when administered intravaginally. Several studies in healthy
postmenopausal women showed that low-dose vaginal estrogens
improve vaginal symptoms in most treated subjects, with plasma
estradiol levels in the range of postmenopausal value.34-36 Ultra-low
doses of vaginal estrogens have been recently investigated in post-
menopausal healthy symptomatic women,37-39 showing good effi-
cacy and a very favorable safety profile on breast and endometrium,
with negligible plasma levels. Systemic absorption of vaginal estro-
gens can be relevant for BCSs, in particular for those receiving AIs,
which completely deprive the female body of estrogens. Because
results of many in vitro studies suggest that long-term estradiol
deprivation causes an upregulation of estrogen receptors alpha as
well as upregulation of growth factor pathways with consequent
hypersensitivity of cancer cells to low concentrations of estrogens,
serious concern might exist.40 Standard doses of vaginal estrogens
can determine an increase in plasma levels of serum estradiol,
relevant for BCSs, especially for those receiving AIs, as shown in the
study of Kendall et al.28 In this study, 6 postmenopausal BCSs
treated with AIs received estradiol tablets at a standard dose
(25 mg); serum estradiol levels increased from baseline levels
of < 5 pmol/L to a mean of 72 pmol/L at week 2; however, a
decrease to a mean of 16 pmol/L was observed after 1 month.
On the contrary, studies among BCSs using low29,32 and ultra-
low doses31 of vaginal estrogens showed that they can alleviate
VVA symptoms without raising serum levels of estrogens. Previous
published data from our department showed the efficacy and safety
of 2 low-dose vaginal estrogen treatments (estriol cream 0.25 mg or
estradiol tablets 12.5 mg) and of a nonhormonal polycarbophil-
based vaginal moisturizer (2.5 g) administered twice a week for
12 weeks in postmenopausal BCSs with urogenital atrophy. Estra-
diol levels increased by a mean of 3.5 pg/mL in women who
received vaginal estriol cream and by a mean of 2.7 pg/mL in the
Nicoletta Biglia et algroup treated with micronized estradiol tablets.29 In a prospective,
randomized study on 10 postmenopausal BCSs using AIs it was
reported that the daily use of 0.5 mg estriol for 2 weeks did not
result in increased serum levels of estriol or estradiol.32 In a phase I
clinical study with an ultra-low dose of 0.03 mg estriol and lacto-
bacillus combination vaginal tablets in 16 BCSs with VVA, after 3
months of treatment compared with baseline, serum estrone and
estradiol did not increase in any of the women at any time. Serum
estriol transiently increased after the first application in 15 of 16
women, with a maximum of 168 pg/mL 2 to 3 hours after insertion;
after 4 weeks serum estriol was slightly increased in 8 women.31
Vaginal dryness and quality of sexual life continuously improved
during the study period.41 Only 2 studies directly assessed the risk
of recurrence in BCSs using vaginal estrogens: in the study from
Dew et al27 no increase in the recurrence rate in BCSs was observed
whereas O’Meara et al observed no increase in recurrence rate or
mortality, regardless of the total amount of vaginal estrogens used.26
Currently, it is not possible to determine the safety of vaginal
estrogens in BCSs, because of the limitations of small sample size
and design of the available studies and because they only report
about the effect of these treatments on estrogen circulating levels.
However, available data from the literature do not show an
increased risk of cancer recurrence among women with current or
previous breast cancer who use vaginal estrogen to relieve GSM.12
In the recent ACOG bulletin, even if a nonhormonal approach is
considered the first-line treatment for GSM in BCSs during and
after treatment, low-dose vaginal estrogens are indicated as an
option for BCSs unresponsive to nonhormonal remedies.12 The
decision to use vaginal estrogen must be taken in accordance with
the oncologist and must be preceded by an informed consent pro-
cess considering benefits and potential risks of low-dose vaginal
estrogen.12 When vaginal estrogens are used, they should be pre-
scribed at the lowest dose and for a limited period until symptoms
improve.12 Treatment should be individualized on the basis of each
woman’s risk-benefit ratio and clinical presentation.12
In this survey, vaginal estrogen therapy was prescribed by 21% of
the oncologists, especially in cases of severe dyspareunia after the
woman’s request or for recurrent vaginal or urinary infections, even
if with limitations. Approximately one-fourth of the oncologists
who prescribe vaginal estrogen therapy consider it only for women
with nonhormone-dependent cancer whereas the others prescribe it
to patients with hormone-dependent cancer only after the end of
the antihormone adjuvant treatment period. Moreover, when a
gynecologist prescribes vaginal estrogen therapy to a patient, only
few oncologists confirm the prescription without limitations, others
confirm the prescription only for a short period or if the patient has
nonhormone-dependent cancer, whereas 20% of the oncologists
refuse it. Hormonal treatment is considered safe only by 15% of the
oncologists and effective by most of them. According to oncologists’
opinion, women are also concerned about safety of vaginal estrogen:
many women refuse therapy, ask for reassurance, or only accept it if
they have severe symptoms.
The main obstacles for the oncologists in prescribing vaginal
estrogens are the probability of increased cancer recurrence risk and
the possible interference with antihormone adjuvant treatments. In
particular, the use of vaginal estrogens might be appropriate forwomen with GSM using tamoxifen, because low and temporary
increases of plasma estrogen do not appear to increase recurrence
risk because of a competitive interaction with the estrogen receptor.1
For this reason, women receiving AIs who experience GSM
refractory to nonhormonal approaches might benefit from the
short-term use of estrogen with tamoxifen to improve symptoms,
followed by a return to AIs.12
When exploring the oncologists’ knowledge on VVA treatment
options, in most of the cases only standard high-dose formulations
are mentioned and little is known about low and ultra-low doses of
vaginal estrogens. Only half of respondents knew of low-dose and
gel formulations.
Furthermore, only few oncologists were informed about the most
innovative therapies for VVA in BCSs, such as vaginal laser or other
physical therapies.14 In recent years, microablative fractional CO2
laser has become an efficient and safe system that acts through a
mechanism of a microablative action that stimulates tissue remod-
eling.42 Such a process involves interaction with heat shock proteins
43, 47, and 70,43 which induce a local increase in different cyto-
kines, specifically transforming growth factor-A (stimulating matrix
proteins such as collagen), basic fibroblast growth factor (stimulating
angiogenic activity with endothelial cell migration and proliferation),
epidermal growth factor (stimulating re-epithelization), platelet-
derived growth factor (stimulating fibroblasts to produce extracellular
matrix components), and vascular endothelial growth factor (regu-
lating vasculogenesis and angiogenesis) activating fibroblasts to pro-
duce new collagen, other components of the extracellular matrix
(proteoglycans, glycosaminoglycans, and other molecules), and new
vessels, with specific effects on epithelial tissue.42-44
Two laser technologies have been testing in VVA: CO2 laser and
Erbium laser. The efficacy and feasibility of fractional CO2 laser in
the treatment of VVA symptoms in postmenopausal women was
evaluated in the pilot study of Salvatore et al.45 Vaginal dryness,
burning, itching, dyspareunia, and dysuria were significantly
improved at the 12-week follow-up with minimal discomfort
experienced after 3 applications of laser treatment; a significant
improvement of sexual function and satisfaction in sexual life in
postmenopausal women with VVA symptoms was also docu-
mented.46 The most recent study by Siliquini et al47 confirmed that
CO2 laser treatment induced significant improvement of VVA
symptoms, in particular, after 3 treatments; objective and subjective
parameters indicated no VVA and this improvement was long-
lasting to a 15-month follow-up. Also the time of follow-up was
correlated with better objective and subjective scores.
The efficacy of another type of vaginal laser, the Erbium laser,
was evaluated in the pilot study of Gambacciani et al,48 which
showed improvement in GSM, in particular of the symptoms of
vaginal dryness, dyspareunia, and mild to moderate stress urinary
incontinence.
For these reasons, oncologists complain they do not receive
enough information on VVA treatment options.
Conclusion
In conclusion, GSM is a relevant problem for BCSs because it has
a negative influence on QoL and because it can affect patients’
compliance to adjuvant treatment.Clinical Breast Cancer Month 2017 - 5
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problem and wait for a specific request from the patient.
Approximately 70% of the oncologists are against vaginal estro-
genic therapy. The remaining 30% prescribe it, in particular in case
of patients with non hormone-dependent cancer.
Oncologists do not receive enough information on the topic, in
particular little is known about the different types of vaginal es-
trogenic therapy and on the other possible treatments for VVA in
BCSs, such as vaginal laser. They mentioned mainly high doses
vaginal estrogens and they were not well informed regarding new
formulations, like low-dose vaginal estrogen gel.
The most frequently prescribed treatments are nonhormonal
moisturizers or lubricants; they are considered safe but not very
effective by the oncologists.
Great effort must be done to correctly inform health care pro-
viders about the VVA problem and on the available treatments.
Because the number of patients required to perform a random-
ized clinical trial on this topic is huge, it seems difficult to have a
study with enough statistical meaning to show the safety of vaginal
estrogens. For this reason, it is important to inform patients of the
limits of the available studies, and discuss risks and benefits to allow
patients to choose according to their priorities.
Clinical Practice Points
 VVA is an important problem for BCSs; in particular for those
under AIs
 Vaginal non-hormonal treatment is the first line approach to
VVA; however for patients unresponsive to non-hormonal
therapies, vaginal low dose estrogens can be proposed, after
discussion of risks and benefits
 Among health care providers there is reluctance in the use of
vaginal estrogens
 In this survey we assessed the attitude of Breast Oncologists
towards VVA:
B Only half of the Oncologists directly illustrates VVA to the
patients as a possible consequence of premature
menopause induced by adjuvant treatments
B Only around one third of the Oncologists self-manages
VVA treatment, while forty percent refers BCSs to a
gynaecologist to define VVA treatment
B Non-hormonal treatments such as lubricants or moistur-
izers are preferred by most the oncologists
B The main reason not to prescribe vaginal oestrogen therapy
in BCSs is the fear of increased cancer recurrence, the
possible interference with tamoxifen or AIs and the fear
of medical litigation
B In selected cases (for non-hormone dependent breast can-
cer or for hormone dependent tumors, after the
completion of anti-hormone adjuvant treatment), one-
forth of the Oncologists considers using vaginal
oestrogens
B Only half of the respondents know low-dose and gel
formulation of vaginal estrogens
 Because of the relevance of the problem, great effort should be
done in order to correctly inform health care providers about
VVA problems and on the different available treatmentsnical Breast Cancer Month 2017Acknowledgments
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